Do analysts prefer HSAQ or HSCS?

HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 182.69%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts clearly believe HeartSciences is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, HSAQ or HSCS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A HeartSciences N/A N/A -$9.14M -$3.22 N/A

Is HSAQ or HSCS more profitable?

Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Health Sciences Acquisitions Co. 2 N/A N/A -2.38% HeartSciences N/A -816.90% -181.97%

Is RNXT or HSCS more profitable?

HeartSciences has a net margin of 0.00% compared to RenovoRx's net margin of -469.02%. RenovoRx's return on equity of -136.34% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -469.02% -136.34% -104.36% HeartSciences N/A -816.90% -181.97%

Does the media favor RNXT or HSCS?

In the previous week, RenovoRx had 7 more articles in the media than HeartSciences. MarketBeat recorded 9 mentions for RenovoRx and 2 mentions for HeartSciences. HeartSciences' average media sentiment score of 0.56 beat RenovoRx's score of -0.69 indicating that HeartSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Negative HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer HSCS or DXR?

HeartSciences currently has a consensus target price of $8.00, suggesting a potential upside of 182.69%. Given HeartSciences' higher probable upside, research analysts clearly believe HeartSciences is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, HSCS or DXR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartSciences N/A N/A -$9.14M -$3.22 N/A Daxor N/A N/A N/A N/A N/A

Is HSCS or DXR more profitable?

Daxor's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -816.90% -181.97% Daxor N/A N/A N/A

Is MDAI or HSCS more profitable?

HeartSciences has a net margin of 0.00% compared to Spectral AI's net margin of -69.27%. Spectral AI's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Spectral AI -69.27% N/A -78.56% HeartSciences N/A -816.90% -181.97%

Do analysts recommend QTEX or HSCS?

HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 182.69%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts clearly believe HeartSciences is more favorable than QTREX Quantum. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QTREX Quantum 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, QTEX or HSCS?

HeartSciences has lower revenue, but higher earnings than QTREX Quantum. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio QTREX Quantum $290K 127.68 -$13.22M N/A N/A HeartSciences N/A N/A -$9.14M -$3.22 N/A

Is QTEX or HSCS more profitable?

QTREX Quantum's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets QTREX Quantum N/A N/A N/A HeartSciences N/A -816.90% -181.97%

Does the media favor QTEX or HSCS?

In the previous week, HeartSciences had 1 more articles in the media than QTREX Quantum. MarketBeat recorded 2 mentions for HeartSciences and 1 mentions for QTREX Quantum. HeartSciences' average media sentiment score of 0.56 beat QTREX Quantum's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QTREX Quantum 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

HeartSciences (HSCS) Competitors

$2.82 -0.01 (-0.21%)

As of 12:51 PM Eastern

Compare

HSCS vs. HSAQ, RNXT, DXR, MDAI, and QTEX

Should you buy HeartSciences stock or one of its competitors? HeartSciences's main competitors and comparable companies include Health Sciences Acquisitions Co. 2 (HSAQ), RenovoRx (RNXT), Daxor (DXR), Spectral AI (MDAI), and QTREX Quantum (QTEX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does HeartSciences compare to Health Sciences Acquisitions Co. 2?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
HeartSciences	N/A	-816.90%	-181.97%

In the previous week, HeartSciences had 2 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 2 mentions for HeartSciences and 0 mentions for Health Sciences Acquisitions Co. 2. HeartSciences' average media sentiment score of 0.56 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Health Sciences Acquisitions Co. 2	Neutral
HeartSciences	Positive

HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 182.69%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts clearly believe HeartSciences is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Comparatively, 4.9% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

HeartSciences beats Health Sciences Acquisitions Co. 2 on 6 of the 11 factors compared between the two stocks.

How does HeartSciences compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by insiders. Comparatively, 4.9% of HeartSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

RenovoRx currently has a consensus price target of $8.50, indicating a potential upside of 652.21%. HeartSciences has a consensus price target of $8.00, indicating a potential upside of 182.69%. Given RenovoRx's stronger consensus rating and higher possible upside, equities research analysts clearly believe RenovoRx is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has a net margin of 0.00% compared to RenovoRx's net margin of -469.02%. RenovoRx's return on equity of -136.34% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-469.02%	-136.34%	-104.36%
HeartSciences	N/A	-816.90%	-181.97%

RenovoRx has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

In the previous week, RenovoRx had 7 more articles in the media than HeartSciences. MarketBeat recorded 9 mentions for RenovoRx and 2 mentions for HeartSciences. HeartSciences' average media sentiment score of 0.56 beat RenovoRx's score of -0.69 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Negative
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HeartSciences has lower revenue, but higher earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	45.53	-$11.17M	-$0.31	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

Summary

RenovoRx beats HeartSciences on 10 of the 16 factors compared between the two stocks.

How does HeartSciences compare to Daxor?

HeartSciences (NASDAQ:HSCS) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

HeartSciences currently has a consensus target price of $8.00, suggesting a potential upside of 182.69%. Given HeartSciences' higher probable upside, research analysts clearly believe HeartSciences is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Daxor's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-816.90%	-181.97%
Daxor	N/A	N/A	N/A

In the previous week, HeartSciences had 2 more articles in the media than Daxor. MarketBeat recorded 2 mentions for HeartSciences and 0 mentions for Daxor. HeartSciences' average media sentiment score of 0.56 beat Daxor's score of 0.00 indicating that HeartSciences is being referred to more favorably in the media.

Company	Overall Sentiment
HeartSciences	Positive
Daxor	Neutral

HeartSciences has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Daxor has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 4.9% of HeartSciences shares are held by insiders. Comparatively, 51.5% of Daxor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

HeartSciences beats Daxor on 5 of the 9 factors compared between the two stocks.

How does HeartSciences compare to Spectral AI?

Spectral AI (NASDAQ:MDAI) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

HeartSciences has a net margin of 0.00% compared to Spectral AI's net margin of -69.27%. Spectral AI's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-69.27%	N/A	-78.56%
HeartSciences	N/A	-816.90%	-181.97%

In the previous week, HeartSciences had 2 more articles in the media than Spectral AI. MarketBeat recorded 2 mentions for HeartSciences and 0 mentions for Spectral AI. HeartSciences' average media sentiment score of 0.56 beat Spectral AI's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Spectral AI	Neutral
HeartSciences	Positive

Spectral AI has higher revenue and earnings than HeartSciences. Spectral AI is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65M	2.44	-$7.57M	-$0.35	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

Spectral AI presently has a consensus target price of $4.00, suggesting a potential upside of 168.46%. HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 182.69%. Given HeartSciences' higher possible upside, analysts clearly believe HeartSciences is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Spectral AI has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

67.1% of Spectral AI shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 13.7% of Spectral AI shares are held by insiders. Comparatively, 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Spectral AI beats HeartSciences on 9 of the 15 factors compared between the two stocks.

How does HeartSciences compare to QTREX Quantum?

QTREX Quantum (NASDAQ:QTEX) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 182.69%. Given HeartSciences' stronger consensus rating and higher possible upside, analysts clearly believe HeartSciences is more favorable than QTREX Quantum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QTREX Quantum	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

QTREX Quantum has a beta of 3.97, suggesting that its stock price is 297% more volatile than the broader market. Comparatively, HeartSciences has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

12.7% of QTREX Quantum shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 29.4% of QTREX Quantum shares are held by insiders. Comparatively, 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

QTREX Quantum's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QTREX Quantum	N/A	N/A	N/A
HeartSciences	N/A	-816.90%	-181.97%

In the previous week, HeartSciences had 1 more articles in the media than QTREX Quantum. MarketBeat recorded 2 mentions for HeartSciences and 1 mentions for QTREX Quantum. HeartSciences' average media sentiment score of 0.56 beat QTREX Quantum's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QTREX Quantum	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HeartSciences has lower revenue, but higher earnings than QTREX Quantum.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QTREX Quantum	$290K	127.68	-$13.22M	N/A	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

Summary

HeartSciences beats QTREX Quantum on 7 of the 12 factors compared between the two stocks.

Get HeartSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSCS vs. The Competition

Export

Metric	HeartSciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.99M	$6.16B	$7.89B	$12.10B
Dividend Yield	N/A	1.68%	2.47%	4.47%
P/E Ratio	-0.87	37.99	33.87	30.70
Price / Sales	3,105.21	5.20	8.94	5.59
Price / Cash	N/A	23.49	21.62	22.24
Price / Book	40.34	5.29	4.93	4.06
Net Income	-$9.14M	$144.46M	$3.51B	$390.61M
7 Day Performance	-5.55%	1.34%	1.58%	0.15%
1 Month Performance	-11.19%	-0.25%	-3.71%	-6.05%
1 Year Performance	8.20%	2.21%	3.33%	-5.00%

HeartSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSCS HeartSciences	2.3012 of 5 stars	$2.82 -0.2%	$8.00 +183.3%	+8.4%	$13.99M	$4.52K	N/A	14
HSAQ Health Sciences Acquisitions Co. 2	N/A	$5.78 +4.1%	N/A	+49.1%	$64.81M	N/A	N/A	4	Gap Down
RNXT RenovoRx	2.8443 of 5 stars	$1.43 +2.5%	$8.50 +496.5%	+17.5%	$64.31M	$1.98M	N/A	17	Earnings Report Analyst Downgrade Analyst Revision Gap Up
DXR Daxor	N/A	$8.97 +0.9%	N/A	-34.8%	$52.37M	$8.15M	N/A	37
MDAI Spectral AI	1.9272 of 5 stars	$1.56 +2.0%	$4.00 +156.4%	-23.2%	$50.22M	$19.65M	N/A	65	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSCS) was last updated on 11/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartSciences (HSCS) Competitors

HSCS vs. HSAQ, RNXT, DXR, MDAI, and QTEX

How does HeartSciences compare to Health Sciences Acquisitions Co. 2?

Summary

How does HeartSciences compare to RenovoRx?

Summary

How does HeartSciences compare to Daxor?

Summary

How does HeartSciences compare to Spectral AI?

Summary

How does HeartSciences compare to QTREX Quantum?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartSciences (HSCS) Competitors

HSCS vs. HSAQ, RNXT, DXR, MDAI, and QTEX

How does HeartSciences compare to Health Sciences Acquisitions Co. 2?

Is HSAQ or HSCS more profitable?

Does the media favor HSAQ or HSCS?

Do analysts prefer HSAQ or HSCS?

Which has more volatility and risk, HSAQ or HSCS?

Which has better valuation & earnings, HSAQ or HSCS?

Do insiders and institutionals hold more shares of HSAQ or HSCS?

Summary

How does HeartSciences compare to RenovoRx?

Do insiders & institutionals have more ownership in RNXT or HSCS?

Do analysts rate RNXT or HSCS?

Is RNXT or HSCS more profitable?

Which has more volatility and risk, RNXT or HSCS?

Does the media favor RNXT or HSCS?

Which has better earnings & valuation, RNXT or HSCS?

Summary

How does HeartSciences compare to Daxor?

Which has preferable earnings & valuation, HSCS or DXR?

Do analysts prefer HSCS or DXR?

Is HSCS or DXR more profitable?

Does the media refer more to HSCS or DXR?

Which has more risk and volatility, HSCS or DXR?

Do institutionals and insiders hold more shares of HSCS or DXR?

Summary

How does HeartSciences compare to Spectral AI?

Is MDAI or HSCS more profitable?

Does the media favor MDAI or HSCS?

Which has preferable earnings & valuation, MDAI or HSCS?

Do analysts recommend MDAI or HSCS?

Which has more volatility & risk, MDAI or HSCS?

Do insiders and institutionals believe in MDAI or HSCS?

Summary

How does HeartSciences compare to QTREX Quantum?

Do analysts recommend QTEX or HSCS?

Which has more volatility & risk, QTEX or HSCS?

Do insiders and institutionals believe in QTEX or HSCS?

Is QTEX or HSCS more profitable?

Does the media favor QTEX or HSCS?

Which has preferable earnings & valuation, QTEX or HSCS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSCS vs. The Competition

HeartSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools